Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	PolarityTE	Windtree Therapeutics	Enzon Pharmaceuticals	Microbot Medical	Idera Pharmaceuticals
Symbol	NASDAQ:PTE	NASDAQ:WINT	OTCMKTS:ENZN	NASDAQ:MBOT	NASDAQ:IDRA
Price Information
Current Price	$0.98	$1.76	$0.53	$6.72	$1.02
52 Week Range	Buy	Buy	N/A	Buy	Hold
MarketRank™
Overall Score	1.5	2.3	0.6	1.3	1.8
Analysis Score	3.3	3.5	0.0	3.5	4.0
Community Score	2.7	5.0	2.8	2.8	2.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	0.0	0.0	1.7
Earnings & Valuation Score	1.3	1.3	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	N/A	Buy	Hold
Consensus Price Target	$3.00	$12.25	N/A	$20.00	$4.00
% Upside from Price Target	207.16% upside	596.02% upside	N/A	197.62% upside	292.16% upside
Trade Information
Market Cap	$118.15 million	$46.21 million	$39.33 million	$47.77 million	$51.03 million
Beta	1.29	0.25	0.77	3.98	2.4
Average Volume	8,121,653	460,019	236,904	145,779	2,451,595
Sales & Book Value
Annual Revenue	$5.65 million	$200,000.00	$210,000.00	N/A	$1.45 million
Price / Sales	20.91	231.06	187.30	N/A	35.20
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.42 per share	$5.48 per share	$0.14 per share	$5.02 per share	($0.39) per share
Price / Book	0.69	0.32	3.79	N/A	-2.62
Profitability
Net Income	$-92,490,000.00	$-27,480,000.00	$-980,000.00	$-7,250,000.00	$-56,510,000.00
EPS	($3.70)	($2.52)	N/A	N/A	($1.57)
Trailing P/E Ratio	N/A	N/A	0.00	0.00	N/A
Forward P/E Ratio	N/A	N/A	∞	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-674.12%	N/A	-1,711.94%	N/A	N/A
Return on Equity (ROE)	-169.92%	-43.46%	-20.29%	-28.95%	-771.38%
Return on Assets (ROA)	-105.62%	-26.55%	-18.69%	-26.60%	-34.32%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.08%	0.18%	N/A	N/A	N/A
Current Ratio	3.22%	2.75%	8.91%	29.32%	4.59%
Quick Ratio	3.11%	2.75%	8.91%	29.32%	4.59%
Ownership Information
Institutional Ownership Percentage	16.51%	1.59%	N/A	9.47%	25.05%
Insider Ownership Percentage	5.50%	14.91%	0.03%	8.69%	3.50%
Miscellaneous
Employees	80	31	N/A	14	32
Shares Outstanding	120.97 million	26.26 million	74.22 million	7.11 million	50.03 million
Next Earnings Date	8/5/2021 (Estimated)	8/12/2021 (Estimated)	5/20/2021 (Estimated)	5/21/2021 (Estimated)	8/3/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Contrasting Idera Pharmaceuticals (NASDAQ:IDRA) and ADMA Biologics (NASDAQ:ADMA) americanbankingnews.com - May 14 at 2:10 AM
	Zacks: Brokerages Anticipate Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to Post -$0.20 EPS americanbankingnews.com - May 5 at 7:14 PM
	Why should you add Idera Pharmaceuticals Inc. (IDRA) to your portfolio? marketingsentinel.com - May 5 at 12:38 PM
	What Do Wall Street Analysts Think About Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Stock? stocksregister.com - May 3 at 1:22 PM
	Idera Pharmaceuticals (NASDAQ:IDRA) vs. Genetic Technologies (NASDAQ:GENE) Critical Review americanbankingnews.com - May 2 at 12:14 AM
	Idera Pharmaceuticals (NASDAQ:IDRA) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS americanbankingnews.com - April 30 at 3:42 PM
	Idera: Q1 Earnings Snapshot \| Raleigh News & Observer newsobserver.com - April 29 at 6:07 PM
	Idera: Q1 Earnings Snapshot timesunion.com - April 29 at 6:07 PM
	Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update finance.yahoo.com - April 29 at 6:07 PM
	Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Shares Look Bullish in 2021 stocksregister.com - April 29 at 1:06 PM
	We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate nasdaq.com - April 22 at 7:32 PM
	Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Given Average Recommendation of "Hold" by Brokerages americanbankingnews.com - April 20 at 6:38 PM
	Idera Pharmaceuticals, Inc. (NASDAQ:IDRA): Why Investors Shouldn’t Ditch IDRA stock in 2021 marketingsentinel.com - April 20 at 2:07 PM
	Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Analysis: Is It The One You’re Looking For? stocksregister.com - April 12 at 1:30 PM
	Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2021 Be Worth Your Money? marketingsentinel.com - March 29 at 2:31 PM
	Why Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Stock Might Be A Good Investment stocksregister.com - March 26 at 3:14 PM
	IDRA Stock Price Fell 62%: Why It Happened pulse2.com - March 22 at 7:49 AM
	Thinking about buying stock in Skillz Inc, ZK International, Idera Pharmaceuticals, Upstart Holdings, or Plug Power? prnewswire.com - March 19 at 1:04 PM
	IDRA Stock Price Falls Over 60% Pre-Market: Why It Happened pulse2.com - March 19 at 1:04 PM
	Why Idera Pharmaceuticals Stock Is Crashing Today finance.yahoo.com - March 19 at 1:04 PM
	Latest Biotech Flop Shows Risks of Trading in Penny Stocks finance.yahoo.com - March 19 at 1:04 PM
	Idera Pharmaceuticals stock plunges after disappointing trial results, prompting analyst downgrade finance.yahoo.com - March 19 at 8:04 AM
	Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab ... apnews.com - March 19 at 3:03 AM
$Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma$	Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma finance.yahoo.com - March 19 at 3:03 AM
	Are Options Traders Betting on a Big Move in Idera Pharmaceuticals (IDRA) Stock? finance.yahoo.com - March 18 at 1:04 PM

Date	Company	Brokerage	Action
11/10/2020	PolarityTE	Cantor Fitzgerald	Reiterated Rating
9/8/2020	PolarityTE	Oppenheimer	Reiterated Rating
7/24/2020	PolarityTE	Northland Securities	Reiterated Rating
5/12/2020	PolarityTE	HC Wainwright	Reiterated Rating
11/13/2019	PolarityTE	Piper Jaffray Companies	Lower Price Target
5/13/2019	PolarityTE	National Securities	Lower Price Target
6/26/2020	Windtree Therapeutics	LADENBURG THALM/SH SH	Initiated Coverage
3/25/2021	Idera Pharmaceuticals	JPMorgan Chase & Co.	Reiterated Rating
3/25/2021	Idera Pharmaceuticals	JMP Securities	Reiterated Rating
3/25/2021	Idera Pharmaceuticals	Barclays	Reiterated Rating
3/25/2021	Idera Pharmaceuticals	Wedbush	Reiterated Rating

(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources